Oxidative Stress-Induced Microglial CD22 Upregulation Impairs Phagocytosis and Exacerbates Huntingtons Disease

This study reveals that oxidative stress-induced upregulation of the inhibitory receptor CD22 on microglia impairs phagocytosis and exacerbates Huntington's disease pathology, a mechanism driven by mutant huntingtin-mediated suppression of astrocytic ligands that can be therapeutically targeted to restore microglial function and improve disease outcomes.

The Gist

The Big Picture: A Broken Trash Service in the Brain

Imagine your brain is a bustling, high-tech city. To keep this city running smoothly, it needs a dedicated sanitation crew to clean up trash, dead cells, and toxic debris. In the brain, this crew is made up of microglia (the brain's immune cells).

In Huntington's Disease (HD), the city starts producing a lot of toxic "trash" (a mutated protein called mHTT). Normally, the sanitation crew should step in, eat the trash, and keep the city clean. But in HD, something goes wrong: the crew stops working. They become lazy, ignore the trash, and the city slowly falls apart.

This paper discovers why the crew stops working and how to fix it. The culprit is a "stop sign" on the sanitation trucks that gets stuck in the "ON" position.

---

The Cast of Characters

1. The Microglia (The Sanitation Crew): Their job is to eat debris (phagocytosis).
2. The Astrocytes (The Support Staff): These are helper cells that usually send signals to the sanitation crew to keep them working hard.
3. CD22 (The Broken Stop Sign): This is a protein on the surface of the microglia. Think of it as a brake pedal. When pressed, it tells the microglia to stop eating.
4. Oxidative Stress (The Smog): A type of cellular pollution and stress that happens in HD. It's like a thick, toxic fog that covers the city.
5. The Ligand (The "Go" Signal): A specific sugar molecule produced by the Astrocytes. Think of this as a friendly wave or a green light that tells the microglia to release their brakes and start cleaning.

---

What Went Wrong? (The Mechanism)

The researchers found a chain reaction happening in Huntington's Disease:

1. The Smog Turns Up the Brakes
In HD, the brain is under constant "oxidative stress" (the smog). This stress causes the microglia to install way too many CD22 stop signs on their surfaces. It's like the sanitation trucks suddenly have ten brake pedals instead of one.

2. The Support Staff Stops Waving
Normally, the Astrocytes (Support Staff) produce a special sugar molecule (the "Go" signal) that binds to the CD22 stop sign. When this sugar binds, it actually tells the microglia to release the brakes and start cleaning.
However, in HD, the toxic protein (mHTT) messes with the Astrocytes. Even though the Astrocytes try to make the "Go" signal, the toxic environment stops them from making enough of it.

3. The Result: A Gridlock
Now you have a sanitation crew with too many brakes (high CD22) and no one waving the green light (low sugar signal). The microglia are paralyzed. They can't eat the toxic mHTT trash. The trash piles up, neurons die, and the brain shrinks.

---

How Did They Fix It? (The Solutions)

The researchers tested three different ways to get the sanitation crew working again:

• The "Brake Remover" (Antibody): They used a special antibody (a molecular key) that grabs the CD22 stop sign and pulls it off the surface of the microglia. Without the brake, the microglia immediately started eating the trash again.
• The "Green Light" Delivery (Extracellular Vesicles): They took Astrocytes that were good at making the "Go" signal sugar, packaged it into tiny bubbles (vesicles), and sent them to the microglia. The microglia ate the bubbles, which helped remove the CD22 brakes and restored their cleaning ability.
• The "Delete Button" (Genetic Knockout): They bred mice that didn't have the CD22 gene at all. These mice had no brakes to begin with. Even with the toxic trash, their microglia kept cleaning, the brain stayed healthier, and the mice moved better.

---

The Takeaway

This paper tells us that Huntington's Disease isn't just about the toxic protein damaging neurons directly. It's also about a communication breakdown between the brain's support staff (Astrocytes) and its cleaners (Microglia).

• The Problem: Stress makes the cleaners put on too many brakes, and the support staff stops sending the signal to take them off.
• The Solution: If we can remove the brakes (CD22) or help the support staff send the signal again, we can restore the brain's natural cleaning power.

In simple terms: The brain has a self-cleaning mechanism that gets jammed in Huntington's Disease. This study found the jam (CD22) and showed that if we unjam it, the brain can start cleaning itself up again, slowing down the disease. This makes CD22 a very promising target for new drugs.

Technical Summary

1. Problem Statement

Huntington's Disease (HD) is a progressive neurodegenerative disorder characterized by motor dysfunction and striatal neuronal loss caused by mutant huntingtin (mHTT). While the role of neuronal mHTT aggregates is well-established, the contribution of glial cells (microglia and astrocytes) to HD pathogenesis remains incompletely understood. Specifically, microglia in HD exhibit impaired phagocytic clearance of toxic aggregates and myelin debris, yet the molecular mechanisms driving this dysfunction are unclear.

The authors hypothesized that Siglecs (sialic acid-binding immunoglobulin-type lectins), which act as immune checkpoints on microglia, might be dysregulated in HD. They aimed to identify specific Siglecs involved in HD, determine their functional impact on microglial phagocytosis, and elucidate the upstream regulatory mechanisms (e.g., oxidative stress) and ligand interactions (astrocyte-microglia crosstalk) governing this process.

2. Methodology

The study employed a multi-modal approach combining human post-mortem analysis, mouse models, cell biology, and advanced omics technologies:

• Human and Mouse Models:
  • Human: RT-qPCR and single-nucleus RNA sequencing (snRNA-seq) analysis of post-mortem caudate nucleus samples from HD patients vs. non-HD controls.
  • Mouse: Use of the R6/2 transgenic HD mouse model (expressing mHTT exon 1 with 150 CAG repeats) and wild-type (WT) littermates.
  • Genetic Manipulation: Generation of Cd22 knockout (KO) HD mice (R6/2 x Cd22⁻/⁻) and creation of stable cell lines (BV2 microglia, C8-D1A astrocytes) overexpressing WT or mutant CD22, mHTT, or the enzyme CHST2.
• Omics and Profiling:
  • Mass Cytometry (CyTOF): Used to profile Siglec expression across heterogeneous microglial subpopulations in HD vs. WT brains.
  • Glycomics: Mass spectrometry (MALDI-TOF and LC-MS/MS) to identify N-glycan structures, specifically searching for sulfated and sialylated ligands for CD22.
  • snRNA-seq: To map cell-type-specific expression of Siglecs and glycosyltransferases (e.g., Chst2, St6gal1).
• Functional Assays:
  • Phagocytosis: Assessed using pHrodo™ Red Zymosan beads and myelin debris uptake in BV2 cells and primary microglia.
  • Signaling Mechanisms: Proximity Ligation Assay (PLA) and co-immunoprecipitation to investigate CD22 interaction with phagocytic receptors (e.g., Dectin-1) and ITIM-ITAM signaling.
  • Intervention: Treatment with a neutralizing anti-CD22 antibody (Cy34.1), antioxidant (N-acetylcysteine, NAC), and astrocyte-derived extracellular vesicles (EVs).
• In Vivo Phenotyping:
  • Behavioral tests (rotarod, limb clasping).
  • MRI for brain volume analysis (atrophy).
  • Immunofluorescence for mHTT aggregates, Darpp32 (neuronal marker), and CD68 (phagocytic marker).

3. Key Contributions

• Identification of CD22 as a Pathogenic Driver: The study identifies CD22 (Siglec-2) as the primary Siglec upregulated in microglia during HD progression in both human patients and mouse models.
• Mechanism of Phagocytic Inhibition: It demonstrates that CD22 suppresses microglial phagocytosis via ITIM-ITAM signaling crosstalk (recruiting SHP-1 to dephosphorylate ITAM-bearing phagocytic receptors like Dectin-1). Crucially, this inhibition is independent of CD22's sialic acid-binding domain.
• Discovery of a Ligand-Dependent Regulatory Axis: The authors identified $\alpha$2,6-sialylated-6-sulfo-LacNAc as the primary natural ligand for CD22 in the brain, produced primarily by astrocytes via the enzyme CHST2.
• The "Double Hit" Mechanism in HD: The study reveals a dual failure mechanism in HD:
  1. Microglia: Chronic oxidative stress drives CD22 upregulation.
  2. Astrocytes: mHTT expression in astrocytes under oxidative stress suppresses Chst2 expression, reducing the production of the CD22 ligand.
  • Normally, astrocyte-derived ligands (delivered via EVs) bind CD22, inducing its internalization and relieving phagocytic inhibition. In HD, the lack of ligand prevents this "off-switch," leaving CD22 on the surface to chronically inhibit phagocytosis.
• Therapeutic Validation: Genetic deletion of CD22 or pharmacological depletion of surface CD22 (via antibody or ligand-enriched EVs) restores phagocytosis and ameliorates HD pathology.

4. Key Results

• CD22 Upregulation: CD22 transcripts and protein levels are significantly elevated in the striatum of HD patients and R6/2 mice (specifically in a disease-associated microglial subset expressing AXL and low P2RY12).
• Phagocytosis Impairment: Overexpression of CD22 impairs phagocytosis of zymosan and myelin debris. This effect is abolished in Cd22⁻/⁻ microglia or when surface CD22 is depleted by the Cy34.1 antibody.
• Signaling Pathway: CD22 inhibits phagocytosis through ITIM-mediated recruitment of SHP-1, which dephosphorylates ITAM-bearing receptors (e.g., Dectin-1). This occurs even with a sialic acid-binding-deficient CD22 mutant (R130A), confirming the mechanism is sialic acid-independent.
• Oxidative Stress Link:
  • Oxidative stress specifically upregulates CD22 in microglia.
  • Antioxidant treatment (NAC) normalizes CD22 levels in HD mice.
• Astrocyte-Microglia Crosstalk:
  • Astrocytes express high levels of Chst2 and St6gal1 to synthesize the CD22 ligand ($\alpha$2,6-sialylated-6-sulfo-LacNAc).
  • In HD, mHTT suppresses Chst2 under oxidative stress, leading to a reduction in CD22 ligand on astrocytes.
  • Astrocyte-derived EVs carrying this ligand can induce CD22 internalization in microglia, restoring phagocytosis. This effect is lost in HD due to reduced ligand production.
• In Vivo Efficacy of CD22 Deletion:
  • Cd22⁻/⁻ HD mice showed improved motor performance (rotarod), reduced mHTT aggregate burden, restored Darpp32 expression, and reduced brain atrophy (striatum, corpus callosum, cerebellum) compared to HD controls.
  • CD22 deletion restored CD68 levels (a phagocytic marker) and reduced pro-inflammatory microglial markers (Gal3).

5. Significance

This paper fundamentally shifts the understanding of HD pathogenesis by highlighting a glyco-immune checkpoint mechanism involving astrocyte-microglia communication.

• Novel Therapeutic Target: CD22 is identified as a promising therapeutic target. Blocking CD22 (genetically or via antibodies) or restoring the ligand supply (via EVs) can rescue microglial function and slow disease progression.
• Mechanistic Insight: It clarifies that microglial dysfunction in HD is not just a failure of activation but an active suppression by an upregulated inhibitory receptor (CD22) driven by oxidative stress and exacerbated by a failure in astrocyte support (ligand deficiency).
• Broader Implications: The findings suggest that similar Siglec-mediated checkpoints may be relevant in other neurodegenerative diseases (e.g., Alzheimer's, where CD22 is also upregulated), offering a new class of immunomodulatory strategies focused on glycan-Siglec interactions.
• Oxidative Stress as a Driver: The study reinforces oxidative stress as a central upstream regulator that simultaneously dysregulates both the inhibitor (CD22) and the activator (ligand synthesis), creating a "perfect storm" for neurodegeneration.